Meeting
2019 ASCO Annual Meeting
Safety and efficacy of docetaxel combined with cisplatin as induction chemotherapy followed by cisplatin concurrent chemoradiotherapy plus gemcitabine as adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A prospective and multicenter phase II trial.
Authors
Zhi Hui Wang
The Fifth Hospital Of Sun Yat-sen University, Zhuhai, China
Zhi Hui Wang , Peijian Peng , Siyang Wang , Yumeng Liu , Zhong Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
ChiCTR-OIC-17011464
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6064)
DOI
10.1200/JCO.2019.37.15_suppl.6064
Abstract #
6064
Poster Bd #
53
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
First Author: Chunmei Bai
Poster
2022 ASCO Annual Meeting
Efficacy and safety of camrelizumab and apatinib combined with induction chemotherapy and concurrent chemoradiotherapy for stage TanyN3M0 nasopharyngeal carcinoma: A phase II QUINTUPLED trial.
First Author: Hu Liang
Poster
2022 ASCO Annual Meeting
Neoadjuvant chemotherapy plus tislelizumab followed by concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A single-arm, phase II trial.
First Author: Qiu-Yan Chen
Poster
2019 ASCO Annual Meeting
Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—An update and retrospective review of non-study patients.
First Author: Robert S. Siegel